busulfan has been researched along with Diffuse Large B-Cell Lymphoma in 23 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We retrospectively examined the outcomes of 56 patients with diffuse large B-cell lymphoma (DLBCL) who underwent autologous stem cell transplant (ASCT) with BEAM/BEAC (carmustine, etoposide, cytarabine, melphalan/cyclophosphamide) or busulfan (Bu)-containing conditioning regimens." | 7.80 | Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma. ( Chung, JS; Kim, H; Kim, JS; Lee, GW; Lee, HS; Lee, WS; Shin, HJ; Song, MK; Yhim, HY, 2014) |
| " The graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and short-term methotrexate." | 4.12 | Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia. ( Ishiguro, C; Kawashiri, A; Kurokawa, T; Maeda, Y; Mochizuki, K; Nakagawa, SI, 2022) |
| "We retrospectively examined the outcomes of 56 patients with diffuse large B-cell lymphoma (DLBCL) who underwent autologous stem cell transplant (ASCT) with BEAM/BEAC (carmustine, etoposide, cytarabine, melphalan/cyclophosphamide) or busulfan (Bu)-containing conditioning regimens." | 3.80 | Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma. ( Chung, JS; Kim, H; Kim, JS; Lee, GW; Lee, HS; Lee, WS; Shin, HJ; Song, MK; Yhim, HY, 2014) |
| "Vorinostat was given at 200 mg/day to 1000 mg/day (days -8 to -3)." | 2.80 | Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. ( Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hagemeister, F; Hosing, C; Jones, RB; Liu, Y; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC, 2015) |
| "Since bone marrow biopsy revealed myelofibrosis, she received anabolic hormone therapy." | 1.35 | [Long-term remission of non-Hodgkin lymphoma secondary to the treatment for essential thrombocythemia]. ( Kubota, Y; Waki, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (30.43) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 5 (21.74) | 24.3611 |
| 2020's | 5 (21.74) | 2.80 |
| Authors | Studies |
|---|---|
| Puckrin, R | 1 |
| Chua, N | 1 |
| Shafey, M | 1 |
| Stewart, DA | 1 |
| Kawashiri, A | 1 |
| Nakagawa, SI | 1 |
| Ishiguro, C | 1 |
| Mochizuki, K | 1 |
| Maeda, Y | 1 |
| Kurokawa, T | 1 |
| Kodama, Y | 1 |
| Saburi, M | 1 |
| Maruyama, R | 1 |
| Sakata, M | 1 |
| Takata, H | 1 |
| Miyazaki, Y | 1 |
| Kawano, K | 1 |
| Wada, J | 1 |
| Urabe, S | 1 |
| Hazuku, T | 1 |
| Ohtsuka, E | 1 |
| Morita, K | 1 |
| Ashizawa, M | 1 |
| Toda, Y | 1 |
| Ikeda, T | 1 |
| Kawaguchi, SI | 1 |
| Ito, S | 1 |
| Ochi, SI | 1 |
| Nagayama, T | 1 |
| Mashima, K | 1 |
| Umino, K | 1 |
| Minakata, D | 1 |
| Nakano, H | 1 |
| Yamasaki, R | 1 |
| Yamamoto, C | 1 |
| Hatano, K | 1 |
| Fujiwara, SI | 1 |
| Sato, K | 1 |
| Oh, I | 1 |
| Ohmine, K | 1 |
| Muroi, K | 1 |
| Matsumoto, K | 1 |
| Kanda, Y | 1 |
| Epperla, N | 1 |
| Ahn, KW | 1 |
| Khanal, M | 1 |
| Litovich, C | 1 |
| Ahmed, S | 2 |
| Ghosh, N | 1 |
| Fenske, TS | 1 |
| Kharfan-Dabaja, MA | 1 |
| Sureda, A | 1 |
| Hamadani, M | 1 |
| Shin, HJ | 1 |
| Lee, WS | 1 |
| Lee, HS | 1 |
| Kim, H | 1 |
| Lee, GW | 1 |
| Song, MK | 1 |
| Kim, JS | 1 |
| Yhim, HY | 1 |
| Chung, JS | 1 |
| Nieto, Y | 1 |
| Valdez, BC | 1 |
| Thall, PF | 1 |
| Jones, RB | 1 |
| Hosing, C | 1 |
| Popat, U | 1 |
| Shpall, EJ | 1 |
| Qazilbash, M | 1 |
| Gulbis, A | 1 |
| Anderlini, P | 1 |
| Alousi, A | 1 |
| Shah, N | 1 |
| Bashir, Q | 1 |
| Liu, Y | 1 |
| Oki, Y | 1 |
| Hagemeister, F | 1 |
| Fanale, M | 1 |
| Dabaja, B | 1 |
| Pinnix, C | 1 |
| Champlin, R | 1 |
| Andersson, BS | 1 |
| Lee, MY | 1 |
| Kim, HS | 1 |
| Lee, JY | 1 |
| Lim, SH | 1 |
| Kang, ES | 1 |
| Ko, YH | 1 |
| Kim, SJ | 1 |
| Kim, WS | 1 |
| Kubota, Y | 1 |
| Waki, M | 1 |
| Miura, Y | 1 |
| Toyooka, N | 1 |
| Iwai, F | 1 |
| Matsui, Y | 1 |
| Hirai, M | 1 |
| Kaneko, H | 1 |
| Watanabe, M | 1 |
| Tsudo, M | 1 |
| Papageorgiou, SG | 1 |
| Diamantopoulos, P | 1 |
| Levidou, G | 1 |
| Angelopoulou, MK | 1 |
| Economopoulou, P | 1 |
| Efthimiou, A | 1 |
| Constantinou, N | 1 |
| Katsigiannis, A | 1 |
| Korkolopoulou, P | 1 |
| Pappa, V | 1 |
| Economopoulou, C | 1 |
| Georgiou, G | 1 |
| Dimou, M | 1 |
| Tsirigotis, P | 1 |
| Kyrtsonis, MC | 1 |
| Kotsianidis, I | 1 |
| Kalpadakis, C | 1 |
| Dimopoulos, MA | 1 |
| Beris, P | 1 |
| Meletis, J | 1 |
| Pangalis, GA | 1 |
| Dervenoulas, J | 1 |
| Panayiotidis, P | 1 |
| Vassilakopoulos, TP | 1 |
| PITNEY, WR | 1 |
| ORIGENES, ML | 1 |
| BEATTY, EC | 1 |
| BRUBAKER, C | 1 |
| HAMMOND, D | 1 |
| HARTMANN, JR | 1 |
| SHORE, N | 1 |
| WILLIAMS, KO | 1 |
| HUTCHISON, JL | 1 |
| MORROW, LB | 1 |
| ANDERSON, RE | 1 |
| Soussain, C | 3 |
| Hoang-Xuan, K | 3 |
| Levy, V | 2 |
| Rodriguez, R | 1 |
| Nademanee, A | 1 |
| Ruel, N | 1 |
| Smith, E | 1 |
| Krishnan, A | 1 |
| Popplewell, L | 1 |
| Zain, J | 1 |
| Patane, K | 1 |
| Kogut, N | 1 |
| Nakamura, R | 1 |
| Sarkodee-Adoo, C | 1 |
| Forman, SJ | 1 |
| Taillandier, L | 1 |
| Fourme, E | 1 |
| Choquet, S | 1 |
| Witz, F | 1 |
| Casasnovas, O | 1 |
| Dupriez, B | 1 |
| Souleau, B | 1 |
| Taksin, AL | 1 |
| Gisselbrecht, C | 1 |
| Jaccard, A | 1 |
| Omuro, A | 1 |
| Sanson, M | 1 |
| Janvier, M | 1 |
| Kolb, B | 1 |
| Zini, JM | 1 |
| Leblond, V | 2 |
| Suzan, F | 1 |
| Cassoux, N | 1 |
| Azar, N | 1 |
| Belanger, C | 1 |
| Achour, E | 1 |
| Ribrag, V | 1 |
| Gerber, S | 1 |
| Delattre, JY | 1 |
| Bolwell, B | 1 |
| Kalaycio, M | 1 |
| Andresen, S | 1 |
| Goormastic, M | 1 |
| McBee, M | 1 |
| Kuczkowski, E | 1 |
| Wise, K | 1 |
| Sobecks, R | 1 |
| Pohlman, B | 1 |
| Armstrong, JG | 1 |
| Schmidt, M | 1 |
| Havemann, K | 1 |
| Hartwich, G | 1 |
| Butzler, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study for Safety and Efficacy of BEB (Bendamustine, Etoposide, Busulfan) Conditioning Regimen for ASCT in Non-Hodgkin's Lymphoma[NCT02836639] | Phase 2 | 20 participants (Anticipated) | Interventional | 2016-02-29 | Recruiting | ||
| Vorinostat (SAHA) Combined With High-Dose Gemcitabine, Busulfan, and Melphalan With Autologous Hematopoietic Cell Support for Patients With Relapsed or Refractory Lymphoid Malignancies[NCT01421173] | Phase 1 | 78 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin®) in Association With a Fludarabine Based Reduced Conditioning Regimen and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.[NCT00607854] | Phase 2 | 31 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841] | Phase 3 | 250 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
3 trials available for busulfan and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Dr | 2015 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; C | 2001 |
20 other studies available for busulfan and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous S | 2022 |
Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia.
Topics: Antilymphocyte Serum; Azacitidine; Busulfan; Epstein-Barr Virus Infections; Graft vs Host Disease; H | 2022 |
[Busulfan/thiotepa followed by autologous peripheral blood stem cell transplantation for refractory diffuse large B-cell lymphoma accompanied by hypopyon].
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Doxorubicin; Humans; Lym | 2022 |
Salvage Chemotherapy Followed by Autologous Stem-Cell Transplantation Using Targeted Busulfan for Refractory Diffuse Large B-Cell Lymphoma With Dialysis-Dependent End-Stage Renal Disease.
Topics: Busulfan; Humans; Kidney Failure, Chronic; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Renal | 2020 |
Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation.
Topics: Adult; Busulfan; Humans; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Transplantatio | 2021 |
Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; | 2014 |
Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B‑cell lymphoma with secondary central nervous system involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System Neoplas | 2015 |
[Long-term remission of non-Hodgkin lymphoma secondary to the treatment for essential thrombocythemia].
Topics: Alkylating Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Co | 2009 |
[Sustained complete remission of intravascular large B-cell lymphoma with recurrent CNS involvement by autologous peripheral blood stem cell transplantation preconditioned with TBC regimen].
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2011 |
Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Chemotherapy of malignant disease. II. Diseases of lymphoid tissue and bone marrow.
Topics: Adrenal Cortex Hormones; Aged; Bone Marrow; Busulfan; Chlorambucil; Cyclophosphamide; Hodgkin Diseas | 1962 |
TRIAL OF HYDROXYUREA (NSC-32065) IN CANCER IN CHILDREN.
Topics: Antineoplastic Agents; Busulfan; Child; Cyclophosphamide; Dactinomycin; Humans; Hydroxyurea; Leukemi | 1964 |
THE MANAGEMENT OF LEUKEMIA AND LYMPHOMA.
Topics: Adrenal Cortex Hormones; Busulfan; Chlorambucil; Cortisone; Cyclophosphamide; Hodgkin Disease; Human | 1964 |
ACTIVE TUBERCULOSIS IN LEUKEMIA. MALIGNANT LYMPHOMA AND MYELOFIBROSIS.
Topics: Alkylating Agents; Aminopterin; Busulfan; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Leu | 1965 |
[Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla | 2004 |
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Busulfan; Cause of Death; Cohort Studies; Cyclophosphamide; Disease-Free Su | 2006 |
Autologous peripheral blood progenitor cell transplantation for transformed diffuse large-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Transformati | 2000 |
Current problems in the use of the oncolytic drugs.
Topics: Antineoplastic Agents; Busulfan; Carcinoma, Squamous Cell; Child; Chlorambucil; Choriocarcinoma; Dac | 1968 |
[Treatment of chronic myeloid leukemia and lymphoreticular sarcoma with piposulfan].
Topics: Adult; Aged; Anemia, Aplastic; Antineoplastic Agents; Busulfan; Female; Humans; Leukemia, Myeloid; L | 1970 |
[Secondary tumors in hemoblastoses during cytostatic treatment].
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Bronchial Neoplasms; Busulfan; Carcinoma; Chlo | 1971 |